Study ID: CTSU S1609
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
This phase II trial studies nivolumab and ipilimumab in treating patients with rare tumors. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Bemidji Clinic, Bismarck Region, Fargo Region, Sioux Falls Region
Preston Steen, MD,Preston Steen, MD,Preston Steen, MD,Preston Steen, MD
RARE (Rare Tumors), Lung, Non-Small Cell Lung Cancer, Other, RST (Soft Tissue Sarcoma), Skin, Soft Tissue, Vulvar
Active - Open to Accrual